About FIJYX
Fidelity Advisor Biotechnology Fund Class Z is a mutual fund designed to achieve capital appreciation by investing primarily in biotechnology companies. The fund allocates at least 80% of its assets to firms engaged in the research, development, manufacture, and distribution of biotechnology products, services, and processes. It may invest in both domestic and foreign companies, targeting those poised to benefit significantly from scientific advancements in the field. The fund emphasizes exposure to innovative sectors within healthcare, such as pharmaceuticals and therapeutic development, and its portfolio is notably concentrated, with over half of assets in its top ten holdings, including industry leaders like AbbVie, Regeneron Pharmaceuticals, and Amgen.
With a competitive expense ratio that falls among the lowest in its category, the fund is positioned as a cost-effective choice for investors seeking targeted exposure to the biotech sector. Its risk profile and performance have been rated above average, reflecting the sector’s volatility and growth potential. By focusing on a dynamic and fast-evolving industry, Fidelity Advisor Biotechnology Fund Class Z plays a specialized role in the market, offering diversification for those seeking to tap into biotechnological innovation and long-term trends in healthcare.
Fund Family Fidelity
Category Health
Performance Rating High
Risk Rating Above Average
Stock Exchange Nasdaq
Ticker Symbol FIJYX
Share Class Class Z
Index S&P 500 TR
FIJYX had a total return of 42.77% in the past year, including dividends. Since the fund's
inception, the average annual return has been 12.94%.
